Peer-influenced content. Sources you trust. No registration required. This is HCN.

ReachMDTreating Psychosis in Schizophrenia: Could a Non-D2-Receptor Binding Drug Be the Key?

For the treatment of psychosis in schizophrenia, may an oral molecule constitute a new class of psychotropic drug with a non-D2-receptor binding mode of action? The purpose of a recent study was to answer that question, which Dr. Matt Birnholz delves into in this audio abstract.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form